U.S. Markets Post Fourth Straight Weekly Loss Amid Middle East Escalation 
U.S. Stock Futures Slide as Iran Conflict and Inflation Fears Rattle Wall Street 
Oil Prices Surge Amid Trump's Iran Ultimatum Over Strait of Hormuz 
Gold Prices Drop Amid Inflation Fears and U.S.-Iran Escalation 
Qatar's Economy Under Pressure: How Regional Conflict Could Reshape Global Investment in 2026 
Goldman Sachs Delays Bank of England Rate Cut Forecast Amid Middle East Inflation Risks 
Asian Currencies Slide as U.S.-Iran Tensions and Rising Oil Prices Rattle Markets 
Federal Reserve Crisis: DOJ Standoff Threatens Powell's Succession and Rate Stability 
Xiaomi Shares Drop After SU7 Launch as Margin Concerns Weigh on Investors 
NVIDIA's Feynman AI Chip May Face Redesign Amid TSMC Capacity Crunch 
US-Iran War: Trump Eyes Military Exit as Markets React to Potential De-escalation 
Netflix Eyes South Korea for More Live Events as BTS Concert Livestream Approaches 
GE Vernova and Hitachi's $40 Billion SMR Investment Signals a New Era for U.S. Nuclear Energy 
Iran-U.S. War Sends Dollar Higher as Middle East Tensions Escalate 
Iran War Fears Send Oil Prices Surging as U.S. Weighs Ground Troop Deployment 
Berkshire Hathaway and Tokio Marine Form Major Strategic Insurance Partnership 
EA's $15B Debt Offering Draws $25B in Investor Demand Amid Credit Market Turmoil 
Moderna has assigned its new chief medical officer after recruiting a former Johnson & Johnson executive. It was reported that effective on July 6, Dr. Paul Burton will be joining the American pharmaceutical and biotechnology company based in Cambridge, Massachusetts.
As per Market Watch, Dr. Burton worked in Janssen Pharmaceuticals as its chief global medical affairs officer from March 2020, but he has been with Johnson & Johnson for 16 years and held various executive positions during his tenure.
Burton moves to Moderna
Dr. Paul Burton will be replacing Tal Zaks, who is said to be leaving Moderna after six years with the company. The incoming Moderna medical chief was also said to have previously worked as the vice president and head of cardiovascular and metabolic medical affairs in J&J.
He will be joining the biotech firm at the time when it is seeking approval from the government’s health regulators so that its COVID-19 vaccine could be used for adolescents too. Moderna’s chief executive officer, Stephane Bancel, said that testing results for the use of the vaccine in children will be available by fall. If the outcome is good, she said that it could help get a nod from the regulators and health safety boards.
“Paul’s extensive medical experience in the global pharmaceutical and biotech industry will be important to Moderna as we expand internationally and continue our journey as a commercial company,” CEO Bancel said in a press release. “As we work to deliver on the promise of mRNA science to create a new generation of transformative medicines for patients, Paul’s expertise across multiple therapeutic areas and his proven track record leveraging data science and digital technologies to reimagine medical engagement will be invaluable.”
Moderna’s foray into COVID-19 vaccine production
Moderna’s name became popular after joining the list of pharmaceutical firms that develop and produce vaccines for COVID-19. Its label was often in the headlines since last year, and now it is considered as one of the leading suppliers of vaccines worldwide.
Moderna’s CEO believes that with Dr. Paul Burton’s expertise, the company will achieve more of its goals in the coming years. She said that she is really looking forward to working with the new medical chief as they could achieve many things together.
